A combination therapy targeting endoglin and VEGF-A prevents subretinal fibro-neovascularization caused by induced müller cell disruption

Shen W., Lee S.-R., Yam M., Zhu L., Zhang T., Pye V., Mathai A.E., Shibagaki K., Zhang J.-Z., Matsugi T., Gillies M.C.

2018
Investigative Ophthalmology and Visual Science

View publication

Therapeutic Area

Back of the eye (BOTE)
Categories

Preclinical development

Affiliations

The University of Sydney, Save Sight Institute Discipline of Ophthalmology, Sydney Medical School, Sydney, NSW, Australia; Department of Non-Clinical Research, Global R&D, Santen Pharmaceutical Co. Ltd., Nara, Japan

Related Publications

Atropine Ophthalmic Solution to Reduce Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind Multicenter Phase II APPLE Study

Chia A, Ngo C, Choudry N, Yamakawa Y, Tan D

Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial

Yoshida T.; Takagi Y.; Igarashi-Yokoi T.; Ohno-Matsui K.

Electrical, Electromagnetic, Ultrasound Wave Therapies, and Electronic Implants for Neuronal Rejuvenation, Neuroprotection, Axonal Regeneration, and IOP Reduction

Sharif, N.A.

View all Back of the eye (BOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022